189 related articles for article (PubMed ID: 17195079)
1. Dendritic cell based antitumor vaccination: impact of functional indoleamine 2,3-dioxygenase expression.
Wobser M; Voigt H; Houben R; Eggert AO; Freiwald M; Kaemmerer U; Kaempgen E; Schrama D; Becker JC
Cancer Immunol Immunother; 2007 Jul; 56(7):1017-24. PubMed ID: 17195079
[TBL] [Abstract][Full Text] [Related]
2. CD4/CD8 + T cells, DC subsets, Foxp3, and IDO expression are predictive indictors of gastric cancer prognosis.
Li F; Sun Y; Huang J; Xu W; Liu J; Yuan Z
Cancer Med; 2019 Dec; 8(17):7330-7344. PubMed ID: 31631566
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of dendritic cell-tumor fusion vaccine potency by indoleamine-pyrrole 2,3-dioxygenase inhibitor, 1-MT.
Ou X; Cai S; Liu P; Zeng J; He Y; Wu X; Du J
J Cancer Res Clin Oncol; 2008 May; 134(5):525-33. PubMed ID: 17909857
[TBL] [Abstract][Full Text] [Related]
4. Silencing IDO in dendritic cells: a novel approach to enhance cancer immunotherapy in a murine breast cancer model.
Zheng X; Koropatnick J; Chen D; Velenosi T; Ling H; Zhang X; Jiang N; Navarro B; Ichim TE; Urquhart B; Min W
Int J Cancer; 2013 Feb; 132(4):967-77. PubMed ID: 22870862
[TBL] [Abstract][Full Text] [Related]
5. A two-step induction of indoleamine 2,3 dioxygenase (IDO) activity during dendritic-cell maturation.
Braun D; Longman RS; Albert ML
Blood; 2005 Oct; 106(7):2375-81. PubMed ID: 15947091
[TBL] [Abstract][Full Text] [Related]
6. Synovial autoreactive T cells in rheumatoid arthritis resist IDO-mediated inhibition.
Zhu L; Ji F; Wang Y; Zhang Y; Liu Q; Zhang JZ; Matsushima K; Cao Q; Zhang Y
J Immunol; 2006 Dec; 177(11):8226-33. PubMed ID: 17114500
[TBL] [Abstract][Full Text] [Related]
7. Glycogen Synthase Kinase-3β (GSK-3β) Inhibition Enhances Dendritic Cell-based Cancer Vaccine Potency via Suppression of Interferon-γ-induced Indoleamine 2,3-Dioxygenase Expression.
Noh KT; Son KH; Jung ID; Kang TH; Choi CH; Park YM
J Biol Chem; 2015 May; 290(19):12394-402. PubMed ID: 25814664
[TBL] [Abstract][Full Text] [Related]
8. Indoleamine 2,3-dioxygenase-expressing leukemic dendritic cells impair a leukemia-specific immune response by inducing potent T regulatory cells.
Curti A; Trabanelli S; Onofri C; Aluigi M; Salvestrini V; Ocadlikova D; Evangelisti C; Rutella S; De Cristofaro R; Ottaviani E; Baccarani M; Lemoli RM
Haematologica; 2010 Dec; 95(12):2022-30. PubMed ID: 20801903
[TBL] [Abstract][Full Text] [Related]
9. CD25 and indoleamine 2,3-dioxygenase are up-regulated by prostaglandin E2 and expressed by tumor-associated dendritic cells in vivo: additional mechanisms of T-cell inhibition.
von Bergwelt-Baildon MS; Popov A; Saric T; Chemnitz J; Classen S; Stoffel MS; Fiore F; Roth U; Beyer M; Debey S; Wickenhauser C; Hanisch FG; Schultze JL
Blood; 2006 Jul; 108(1):228-37. PubMed ID: 16522817
[TBL] [Abstract][Full Text] [Related]
10. Specific subsets of murine dendritic cells acquire potent T cell regulatory functions following CTLA4-mediated induction of indoleamine 2,3 dioxygenase.
Mellor AL; Chandler P; Baban B; Hansen AM; Marshall B; Pihkala J; Waldmann H; Cobbold S; Adams E; Munn DH
Int Immunol; 2004 Oct; 16(10):1391-401. PubMed ID: 15351783
[TBL] [Abstract][Full Text] [Related]
11. Indoleamine 2, 3-dioxygenase (IDO) is essential for dendritic cell activation and chemotactic responsiveness to chemokines.
Hwang SL; Chung NP; Chan JK; Lin CL
Cell Res; 2005 Mar; 15(3):167-75. PubMed ID: 15780178
[TBL] [Abstract][Full Text] [Related]
12. Melanoma-Derived Wnt5a Promotes Local Dendritic-Cell Expression of IDO and Immunotolerance: Opportunities for Pharmacologic Enhancement of Immunotherapy.
Holtzhausen A; Zhao F; Evans KS; Tsutsui M; Orabona C; Tyler DS; Hanks BA
Cancer Immunol Res; 2015 Sep; 3(9):1082-95. PubMed ID: 26041736
[TBL] [Abstract][Full Text] [Related]
13. Macrophages/Microglia Represent the Major Source of Indolamine 2,3-Dioxygenase Expression in Melanoma Metastases of the Brain.
Herrera-Rios D; Mughal SS; Teuber-Hanselmann S; Pierscianek D; Sucker A; Jansen P; Schimming T; Klode J; Reifenberger J; Felsberg J; Keyvani K; Brors B; Sure U; Reifenberger G; Schadendorf D; Helfrich I
Front Immunol; 2020; 11():120. PubMed ID: 32117271
[TBL] [Abstract][Full Text] [Related]
14. Haemophilus ducreyi lipooligosaccharides induce expression of the immunosuppressive enzyme indoleamine 2,3-dioxygenase via type I interferons and tumor necrosis factor alpha in human dendritic cells.
Li W; Katz BP; Spinola SM
Infect Immun; 2011 Aug; 79(8):3338-47. PubMed ID: 21576329
[TBL] [Abstract][Full Text] [Related]
15. IDO expands human CD4+CD25high regulatory T cells by promoting maturation of LPS-treated dendritic cells.
Hill M; Tanguy-Royer S; Royer P; Chauveau C; Asghar K; Tesson L; Lavainne F; Rémy S; Brion R; Hubert FX; Heslan M; Rimbert M; Berthelot L; Moffett JR; Josien R; Grégoire M; Anegon I
Eur J Immunol; 2007 Nov; 37(11):3054-62. PubMed ID: 17948274
[TBL] [Abstract][Full Text] [Related]
16. The therapeutic effect of dendritic cells expressing indoleamine 2,3-dioxygenase (IDO) on an IgA nephropathy mouse model.
Liu K; Yang Y; Chen Y; Li S; Gong Y; Liang Y
Int Urol Nephrol; 2020 Feb; 52(2):399-407. PubMed ID: 31894556
[TBL] [Abstract][Full Text] [Related]
17. Indoleamine 2,3-dioxygenase, by degrading L-tryptophan, enhances carnitine palmitoyltransferase I activity and fatty acid oxidation, and exerts fatty acid-dependent effects in human alloreactive CD4+ T-cells.
Eleftheriadis T; Pissas G; Sounidaki M; Tsogka K; Antoniadis N; Antoniadi G; Liakopoulos V; Stefanidis I
Int J Mol Med; 2016 Nov; 38(5):1605-1613. PubMed ID: 27667153
[TBL] [Abstract][Full Text] [Related]
18. Der p 1 suppresses indoleamine 2, 3-dioxygenase in dendritic cells from house dust mite-sensitive patients with asthma.
Maneechotesuwan K; Wamanuttajinda V; Kasetsinsombat K; Huabprasert S; Yaikwawong M; Barnes PJ; Wongkajornsilp A
J Allergy Clin Immunol; 2009 Jan; 123(1):239-48. PubMed ID: 19058839
[TBL] [Abstract][Full Text] [Related]
19. Human type 1 and type 2 conventional dendritic cells express indoleamine 2,3-dioxygenase 1 with functional effects on T cell priming.
Sittig SP; van Beek JJP; Flórez-Grau G; Weiden J; Buschow SI; van der Net MC; van Slooten R; Verbeek MM; Geurtz PBH; Textor J; Figdor CG; de Vries IJM; Schreibelt G
Eur J Immunol; 2021 Jun; 51(6):1494-1504. PubMed ID: 33675038
[TBL] [Abstract][Full Text] [Related]
20. Immunosuppressive factor blockade in dendritic cells via siRNAs results in objective clinical responses.
Sioud M; Mobergslien A; Sæbøe-Larssen S
Methods Mol Biol; 2015; 1218():269-76. PubMed ID: 25319657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
